Darunavir

Dosing

원내

HIV-infected patients with no Darunavir resistance associated substitutions 800 mg PO q24h with Ritonavir 100 mg PO q24h

Treatment-experienced HIV-infected patients with ≥1 Darunavir resistance associated substitution 600 mg PO q12h with Ritonavir 100 mg PO q12hNo renal dose adjustment

원내

Safety and efficacy in pediatric patients <3y of age have not been established

HIV-infected pediatric patients with no Darunavir resistance associated substitutions 35 mg/kg PO q24h + Ritonavir 7 mg/kg PO q24h

Treatment-experienced HIV-infected pediatric patients with ≥1 Darunavir resistance associated substitution 20 mg/kg PO q12h + Ritonavir 3 mg/kg PO q12hNo renal dose adjustment

Mild or moderate hepatic impairment No dose adjustment

Severe hepatic impairment No data

General Information

Treatment for HIV infection.

Use as part of a 3-drug combination regimen.

Genotypic and phenotypic testing prior to initiation in treatment-experienced patients.

Monitor viral load prior to initiation or modification of ARV treatment at 2-8 weeks.

Monitor CD4 cell counts prior to initiation or with modification of ARV treatment and every 3-6 months; thereafter during at least the first 2 years of treatment.

Monitor hepatitis B screening.

Perform hepatitis C antibody testing prior to initiation or modification of ARV treatment.

Common

  • Rash

  • Hypertriglyceridemia

  • Serum cholesterol raised

  • Abdominal pain

  • Diarrhea

  • Nausea

  • Vomiting

  • Headache

Serious

  • Stevens-Johnson syndrome

  • Generalized exanthematous pustulosis

  • Toxic epidermal necrolysis

  • Diabetes mellitus

  • Pancreatitis

  • Hepatitis

Multiple drug-drug interactions

Antimicrobial class: Antiretroviral agent, HIV-1 protease inhibitor

Pregnancy category: C

Average serum half life:15 hours

Urine penetration: Therapeutic

Precautions: Use with caution in patients with hepatic dysfunction and preexisting (e.g. chronic active hepatitis B or C, cirrhosis, elevated transaminases); interruption or discontinuation of treatment may be necessary.

Insulin initiation or dose adjustment, or oral hypoglycemic agents may be required.

Discontinue immediately if skin reactions are suspected.

Terms of Use | Feedback
© Copyright 2021 Spectrum Mobile Health Inc., dba Firstline Clinical. All rights reserved.